TrialPath
Recruiting

A Study of SL-325 in Crohn's Disease Patients

NCT07753850 · Shattuck Labs, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease
About this study
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
Eligibility criteria
Key Inclusion Criteria: * A diagnosis of Crohn's disease confirmed by endoscopy and histopathology ≥ 3 months prior to Screening * Moderately to severely active CD as defined by CDAI of ≥ 220 and ≤ 450 * SES-CD score ≥ 6 if ileocolonic or colonic disease, or ≥ 4 if isolated ileal disease, as assessed by central review * Demonstrated inadequate response, loss of response, or intolerance to one or more of the following Crohn's disease treatments: corticosteroids, immunomodulators, or an approved anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin (IL)-12/23, anti-interleukin (IL)-23p19, or Janus kinase inhibitor (JAK) Key Exclusion Criteria: * Diagnosis of UC, indeterminate colitis, or any other gastrointestinal condition that could undermine the diagnosis of CD * CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement * Presence or suspicion of any of the following CD complications: intra-abdominal or perianal abscess; symptomatic stricture or colonic stenosis not passable in ileocolonoscopy, fistula, except for perianal fistula; active toxic megacolon or fulminant colitis; short bowel syndrome * Surgical bowel resection within 3 months before Screening, ≥ 3 bowel resections, or previous ileo-colonic resection of \> 2 segments * Diagnosis of primary sclerosing cholangitis * Has a stoma, ileostomy, or colostomy. * Has prior or current gastrointestinal dysplasia, other than a completely removed low-grade dysplastic lesion. * Has active tuberculosis (TB) or inadequately treated latent tuberculosis (LTBI) * Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component
Study design
Enrollment target: 232 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-11-09
Estimated completion: 2030-06
Last updated: 2026-11-12
Interventions
Drug: SL-325Drug: Placebo
Primary outcomes
  • • Proportion of participants who achieve endoscopic response (Week 12)
Sponsor
Shattuck Labs, Inc. · industry
Contacts & investigators
ContactShattuck Medical Director · contact · clinicaltrials@shattucklabs.com · 919-864-2700
All locations (20)
Clinical Trial SiteNot Yet Recruiting
Little Rock, Arkansas, United States
Clinical Trial SiteNot Yet Recruiting
Oxnard, California, United States
Clinical Trial SiteNot Yet Recruiting
Temple City, California, United States
Clinical Trial SiteNot Yet Recruiting
West Hills, California, United States
Clinical Trial SiteNot Yet Recruiting
Inverness, Florida, United States
Clinical Trial SiteRecruiting
Kissimmee, Florida, United States
Clinical Trial SiteNot Yet Recruiting
Naples, Florida, United States
Clinical Trial SiteNot Yet Recruiting
Orlando, Florida, United States
Clinical Trial SiteNot Yet Recruiting
Tampa, Florida, United States
Clinical Trial SiteNot Yet Recruiting
Kansas City, Kansas, United States
Clinical Trial SiteRecruiting
Houma, Louisiana, United States
Clinical Trial SiteNot Yet Recruiting
Marrero, Louisiana, United States
Clinical Trial SiteNot Yet Recruiting
Glen Burnie, Maryland, United States
Clinical Trial SiteNot Yet Recruiting
Boston, Massachusetts, United States
Clinical Trial SiteNot Yet Recruiting
Liberty, Missouri, United States
Clinical Trial SiteNot Yet Recruiting
St Louis, Missouri, United States
Clinical Trial SiteNot Yet Recruiting
Maspeth, New York, United States
Clinical Trial SiteNot Yet Recruiting
Cincinnati, Ohio, United States
Clinical Trial SiteNot Yet Recruiting
Columbus, Ohio, United States
Clinical Trial SiteRecruiting
Nashville, Tennessee, United States
A Study of SL-325 in Crohn's Disease Patients · TrialPath